<DOC>
	<DOCNO>NCT00757705</DOCNO>
	<brief_summary>The purpose study explore maintain efficacy , tolerability , safety flexibly dose paliperidone extended-release ( ER ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) previously unsuccessfully treated oral atypical antipsychotic medication .</brief_summary>
	<brief_title>An Efficacy , Safety And Tolerability Study Flexibly Dosed Paliperidone Extended-Release ( ER ) Participants With Schizophrenia</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , non-randomized ( study drug assign chance ) , single arm , multicenter ( one hospital medical school team work medical research study ) , 24-week study . Participants transition effective dose paliperidone ER oral antipsychotic medication without need titration due lack efficacy , lack tolerability safety , lack compliance reason . A transition period maximum 4 week allow . Throughout study , participant receive flexible dose 3 12 milligram ( mg ) paliperidone daily orally 24 week . Dose adjustment do per Investigator 's discretion base upon participant 's clinical response tolerability study drug . Assessments efficacy perform screen 2 , 4 , 12 24 week . Efficacy primarily evaluate mean Positive Negative Syndrome Scale ( PANSS ) . Participants ' safety also monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Participant meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) criteria schizophrenia Participant give adequate dose appropriate oral atypical antipsychotic adequate period time prior enrollment , previous treatment consider unsuccessful due one follow reason : lack efficacy , lack tolerability safety , lack compliance and/or reason switch another antipsychotic medication Participant legally acceptable representative must sign informed consent document indicate understand purpose procedure require study willing participate study Female participant must postmenopausal least 1 year , surgically sterile , abstinent , , sexually active , agree practice effective method birth control entry throughout study must also negative urine pregnancy test screen Male female , age great equal 18 year Participants clozapine , conventional depot neuroleptic Risperdal CONSTA last 3 month Participants serious unstable medical condition , include know clinically relevant laboratory abnormality Participants history current symptom tardive dyskinesia ( twitch jerk movement control face , tongue , part body ) Participants history neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness ) Participants current use know history ( past 6 month ) substance dependence except nicotine , caffeine , betal nut accord DSMIV Criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone Extended-Release</keyword>
</DOC>